Your browser doesn't support javascript.
loading
A low serum alkaline phosphatase may signal hypophosphatasia in osteoporosis clinic patients.
Ng, Elisabeth; Ashkar, Claudia; Seeman, Ego; Schneider, Hans G; Nguyen, Hanh; Ebeling, Peter R; Sztal-Mazer, Shoshana.
Afiliação
  • Ng E; Department of Endocrinology & Diabetes, Alfred Health, Melbourne, Australia. Elisabeth.Ng@monash.edu.
  • Ashkar C; Department of Endocrinology, Monash Health, Clayton, Australia. Elisabeth.Ng@monash.edu.
  • Seeman E; Department of Endocrinology & Diabetes, Alfred Health, Melbourne, Australia.
  • Schneider HG; Department of Medicine, University of Melbourne, Melbourne, Australia.
  • Nguyen H; Department of Endocrinology, Austin Health, Melbourne, Australia.
  • Ebeling PR; Department of Endocrinology & Diabetes, Alfred Health, Melbourne, Australia.
  • Sztal-Mazer S; Clinical Biochemistry Unit, Alfred Pathology Service, Alfred Health, Melbourne, Australia.
Osteoporos Int ; 34(2): 327-337, 2023 Feb.
Article em En | MEDLINE | ID: mdl-36434431
Low serum alkaline phosphatase (ALP) was found in 9% of patients attending an osteoporosis clinic, 0.6% of hospital patients, and 2/22 with an atypical femoral fracture. Hypophosphatasia was diagnosed in 3% of osteoporosis clinic patients with low ALP. Low ALP is a screening tool for hypophosphatasia, a condition potentially aggravated by antiresorptive therapy. INTRODUCTION: Hypophosphatasia (HPP) is an inherited disorder associated with impaired primary mineralisation of osteoid (osteomalacia). HPP may be misdiagnosed as osteoporosis, a reduction in the volume of normally mineralized bone. Both illnesses may result in fragility fractures, although stress and atypical fractures are more common in HPP. Antiresorptive therapy, first-line treatment for osteoporosis, is relatively contraindicated in HPP. Misdiagnosis and mistreatment can be avoided by recognising a low serum alkaline phosphatase (ALP). Our aim was to determine the prevalence of a low ALP (< 30 IU/L) in patients attending an osteoporosis clinic, in a hospital-wide setting, and in a group of patients with atypical femoral fractures (AFF). METHODS: This was a retrospective study of patients attending an osteoporosis clinic at a tertiary hospital during 8 years (2012-2020). Patients were categorised into those with a transiently low ALP, those with low ALP on ≥ 2 occasions but not the majority of measurements, and those with a persistently low ALP. ALP levels were also assessed in hospital-wide records and a group of patients with AFF. RESULTS: Of 1839 patients attending an osteoporosis clinic, 168 (9%) had ≥ 1 low ALP, 50 (2.7%) had low ALP for ≥ 2 months, and seven (0.4%) had persistently low ALP levels. HPP was diagnosed in five patients, four of whom had persistently low ALP levels. The prevalence of HPP was 0.3% in the osteoporosis clinic and 3% in patients with ≥ 1 low ALP. Low ALP occurred in 0.6% of all hospital patients and 2/22 with AFF. CONCLUSION: Persistently low ALP in osteoporosis clinic attendees is easy to identify and signals the possibility of hypophosphatasia, a condition that may be mistaken for osteoporosis and incorrectly treated with antiresorptive therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteoporose / Fraturas Ósseas / Hipofosfatasia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteoporose / Fraturas Ósseas / Hipofosfatasia Idioma: En Ano de publicação: 2023 Tipo de documento: Article